Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM6V9SC)

Drug Name
ATL-844 Drug Info
Synonyms
N-(4-Cyanophenyl)-2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetamide; MRS 1754; 264622-58-4; MRS-1754; MRS1754; CHEMBL273807; N-(4-cyanophenyl)-2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetamide; N-(4-Cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-acetamide; [3H]MRS1754; [3H]-MRS1754; NCGC00015689-01; Lopac-M-6316; Lopac0_000729; GTPL453; GTPL449; MLS002153324; SCHEMBL1222380; AC1O7G54; CTK8E7916; CHEBI:93269; AOB5542; DTXSID80424967; MolPort-023-276-567; HMS3373J21; HMS3268F13; HMS2230A06; ZINC4475274; BDBM50086170; AKOS027427086; AKOS024457276; EX-3306; ATL-618; ATL-GW-22; ATL-GW-8; A2B adenosine receptor antagonists, Adenosine/Ortho-McNeil; A2B adenosine receptor antagonists (oral, asthma/diabetes), Adenosine Therapeutics; A2B adenosine receptor antagonists (oral, asthma/diabetes), Clinical Data
Cross-matching ID
PubChem CID
6603931
ChEBI ID
CHEMBL273807
CAS Number
CAS 264622-58-4
TTD Drug ID
D01QYQ

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Drug metabolism 2.08 0.00e+0 78/151 (51.66%) FMO2;GSTO1;UGT2B15;...
Retinol metabolism 2.03 0.00e+0 41/68 (60.29%) ALDH1A3;DGAT1;CYP2C18;...
PPAR signaling pathway 1.80 3.52e-2 66/74 (89.19%) FABP5;LPL;FABP4;...
Tyrosine metabolism 1.80 2.64e-2 30/36 (83.33%) DBH;ADH5;TYRP1;...
Renin-angiotensin system 1.80 2.25e-2 20/23 (86.96%) MME;KLK2;ATP6AP2;...
Various types of N-glycan biosynthesis -1.72 4.65e-2 26/39 (66.67%) MAN2A1;MAN2A2;MGAT2;...
Autoimmune thyroid disease -1.78 2.94e-2 46/53 (86.79%) HLA-F;HLA-B;HLA-E;...
Legionellosis -1.79 2.99e-2 51/57 (89.47%) CXCL8;IL1B;NFKB1;...
Allograft rejection -1.84 1.53e-2 32/38 (84.21%) CD80;IL12B;HLA-G;...
Antigen processing and presentation -1.87 1.57e-2 60/78 (76.92%) HSPA1A;IFNG;NFYC;...
Ferroptosis -1.98 6.54e-3 36/41 (87.8%) SLC3A2;SLC11A2;ACSL4;...
Graft-versus-host disease -2.09 0.00e+0 32/42 (76.19%) HLA-G;HLA-DPA1;HLA-DPB1;...
Protein processing in endoplasmic reticulum -2.11 0.00e+0 127/171 (74.27%) MAPK8;BAK1;PDIA4;...
Type I diabetes mellitus -2.18 0.00e+0 38/43 (88.37%) INS;CD80;IL12B;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H